LOTIS-2
LOTIS-2 was the pivotal study for loncastuximab, a CD19 ADC with a DNA-crosslinking payload.
ORR 48.3%, CR 24.1%; median DOR 13.4 months; oedema, effusions, photosensitivity, and liver enzyme rises are class effects of the PBD payload. LOTIS-5 (with rituximab vs R-GemOx) is the confirmatory phase 3.
Setting
R/R DLBCL after ≥2 lines: loncastuximab tesirine (single arm)
Phase
Phase 2
Sponsor
ADC Therapeutics
Registry
Headline result
ORR 48%, CR 24%.
Reported
2021
Enrolled
145
In plain words
What these results mean for people, not percentages
Objective response rateprimaryresponse endpoint
- 48.3 out of 100 people had their tumour shrink with Loncastuximab tesirine.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: R/R DLBCL after ≥2 lines: loncastuximab tesirine (single arm). People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
145 participants enrolled.
Objective response rateprimary
Loncastuximab tesirine48.3 of 100
n = 145
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rateprimary | Loncastuximab tesirine | 145 | 48.3% | — | — | — |